Forwardly’s Ligand Innovation Global Completes Production of First LifeAir G1 Prototypes
October 13, 2021 09:15 ET
| Source: Forwardly, Inc. Mississauga, ON and Henderson, NV, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Dr. Dayo Olakulehin, CEO of Ligand Innovation Global, Inc., (“Ligand”) a partially owned company and partner of Forwardly, Inc. (OTCMKT: FORW), announced today that Ligand has produced two working units of the latest iteration of the LifeAir G1 Portable Ventilator. Upon completion of the production of four additional prototypes, expectedly within the next two weeks, the LifeAir G1 will be fully commissioned.
Ligand also announced that TUV SUD (www.tuvsud.com), an international provider of testing, certification, auditing & advisory services, has booked the LifeAir G1 for external testing during October.
Dr. Olakulehin stated, “We’ve now provided the printed circuit board to Avnet (www.avnet.com) so that they can quote production costs and required lead times. We have started early planning for the production of 1,000 LifeAir G1 units in 2022. We are compelled to begin this planning now because of global supply chain challenges affecting multiple industries, especially considering the global microchip shortage.”
About Ligand Innovation Global, Inc.
Ligand IG continues development of the LifeAir G1 Emergency Portable Ventilator to address the expense of conventional ventilator systems which require the intubation and sedation of the patient. Ligand IG expects these units to become readily available, at a greatly reduced cost, to hospitals, nursing homes, and other sites where emergency, life-saving equipment, such as defibrillators are a necessity. Additional information regarding Ligand IG can be found at www.LigandGlobal.com.